Moedas / KALV
KALV: KalVista Pharmaceuticals Inc
14.52
USD
0.36
(2.42%)
A taxa do KALV para hoje mudou para -2.42%. Paralelamente, o preço mais baixo no mercado atingiu 13.85 e o mais alto foi 14.99.
Veja a dinâmica do par de moedas KalVista Pharmaceuticals Inc. As cotações em tempo real ajudam a reagir rapidamente aos movimentos do mercado. Ao alternar entre os diferentes períodos de tempo, você pode monitorar tendências e movimentos de preços por minuto, hora, dia, semana ou mês. Use estas informações para prever os movimentos do mercado e tomar decisões de negociação informadas.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
KALV Notícias
- Investing Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label
- Investing Kalvista Pharma CEO Palleiko sells $517k in shares
- Investing Kalvista Pharma chief development officer sells $474k in shares
- Investing Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins
- Seeking Alpha KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning (KALV)
- Benzinga Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Abbott Laboratories (NYSE:ABT), Danaher (NYSE:DHR)
- Investing Kalvista stock price target raised to $27 from $19 at JMP on Ekterly pricing
- Investing Kalvista stock rises as Leerink raises price target on FDA approval
- Investing Tesla, Circle Internet Surge Among Monday’s Market Cap Stock Movers
- Investing KalVista stock price target raised to $37 from $22 at BofA on Ekterly approval
- Investing Kalvista stock jumps as Stifel reiterates Buy rating on Ekterly approval
- Investing Tesla, Oracle among Monday’s market cap stock movers
- Benzinga KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Amber International (NASDAQ:AMBR), Baidu (NASDAQ:BIDU)
- Investor's Business Daily KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
- Investing US FDA approves KalVista Pharma’s swelling disorder drug, shares rise
- Benzinga Why Is KalVista Pharmaceuticals Stock Soaring On Monday? - KalVista Pharma (NASDAQ:KALV)
- Investing KalVista stock soars after FDA approves first oral HAE treatment
- Investing FDA approves KalVista’s oral HAE treatment Ekterly
- Investing KalVista grants Pendopharm exclusive rights for sebetralstat in Canada
- Investing Kalvista stock volatile after report of FDA commissioner intervention
- Investor's Business Daily How KalVista Pharma Is Taking On A Rare But Deadly Disease
- Investing FDA delays Kalvista’s sebetralstat decision due to resource constraints
- Investing KalVista’s oral HAE treatment shows efficacy for breakthrough attacks
- Investing Kalvista stock steady as JMP reiterates $19 target amid FDA delay
Faixa diária
13.85
14.99
Faixa anual
7.31
16.32
- Fechamento anterior
- 15.51
- Open
- 14.88
- Bid
- 14.52
- Ask
- 14.82
- Low
- 13.85
- High
- 14.99
- Volume
- 5.171 K
- Mudança diária
- -2.42%
- Mudança mensal
- 29.07%
- Mudança de 6 meses
- 65.75%
- Mudança anual
- -2.16%
12 julho, sábado